Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Altimmune, Inc.ALT · Entity 5349 | Director | December 28, 2017 | January 02, 2018 |
| Lantheus Holdings, Inc.LNTH · Entity 690 | Director | March 03, 2020 | March 05, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Altimmune, Inc.
Report date December 28, 2017 · Filed January 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 589,453 |
Ending reported balance
After 2017-12-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-12-28 · Purchase · Acquired 58,711 · Balance 550,754 F1: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.76 to $2.00 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Row 2 · 2017-12-29 · Purchase · Acquired 38,699 · Balance 589,453 F2: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.90 to $1.98 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. |
| Common Stock, par value $0.0001SEC Table I · non-derivative | IndirectIRA | 12,393 |
Reported balance
Holding disclosure · report date 2017-12-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 12,393 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.76 to $2.00 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price.
F2: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.90 to $1.98 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price.
Lantheus Holdings, Inc.
Report date March 03, 2020 · Filed March 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,089 |
Reported balance
After 2020-03-03 transaction · row 1
1 source rowRow 1 · 2020-03-03 · Grant · Acquired 8,095 · Balance 25,089 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2020 Filed Mar 5, 2020 16:32 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 8,095 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-007201 · doc4.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,089 Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 10,000 | $24.71 | $247,127.00 |
DisclosureSEC source: 0000899243-19-016022 · doc4.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,994 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 1, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.36 to $24.84, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 1,080 | $24.61 | $26,578.15 |
DisclosureSEC source: 0000899243-19-015598 · doc4.xml · nonDerivative · entry 3 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,994 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 1, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.59 to $24.65 , inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 8,920 | $24.11 | $215,080.82 |
DisclosureSEC source: 0000899243-19-015598 · doc4.xml · nonDerivative · entry 2 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,074 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 1, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.59 to $24.58 , inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 10,000 | $23.47 | $234,725.00 |
DisclosureSEC source: 0000899243-19-015598 · doc4.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,994 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 1, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.25 to $23.78, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 10,000 | $24.41 | $244,094.00 |
DisclosureSEC source: 0000899243-19-009765 · doc4.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,994 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.11 to $25.00, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 16:21 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 5,353 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005223 · doc4.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,994 Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 16:32 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 7,911 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006646 · doc4.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,641 Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 17:09 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 38,699 | $1.93 | $74,778.08 |
DisclosureSEC source: 0001012975-18-000006 · edgar.xml · nonDerivative · entry 2 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589,453 F2 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.90 to $1.98 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 17:09 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 58,711 | $1.92 | $112,672.28 |
DisclosureSEC source: 0001012975-18-000006 · edgar.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,754 F1 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.76 to $2.00 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 27, 2017 Filed Dec 27, 2017 18:27 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 27,706 | $1.77 | $49,039.62 |
DisclosureSEC source: 0001012975-17-000955 · edgar.xml · nonDerivative · entry 4 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,043 Read SEC document |
| December 27, 2017 Filed Dec 27, 2017 18:27 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 50,000 | $1.76 | $88,170.00 |
DisclosureSEC source: 0001012975-17-000955 · edgar.xml · nonDerivative · entry 3 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,337 F3 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.738075 to $1.77 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 26, 2017 Filed Dec 27, 2017 18:27 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 51,442 | $1.81 | $93,269.49 |
DisclosureSEC source: 0001012975-17-000955 · edgar.xml · nonDerivative · entry 2 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,337 F2 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.64 to $1.99 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 22, 2017 Filed Dec 27, 2017 18:27 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 17,982 | $1.61 | $28,877.29 |
DisclosureSEC source: 0001012975-17-000955 · edgar.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,895 F1 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.52 to $1.68 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 17:51 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 7,639 | $1.74 | $13,307.90 |
DisclosureSEC source: 0001012975-17-000923 · edgar.xml · nonDerivative · entry 2 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,913 F2 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.70 to $1.79 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 17:51 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 16,106 | $1.80 | $28,995.63 |
DisclosureSEC source: 0001012975-17-000923 · edgar.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,274 F1 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.76 to $1.86 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 05, 2017 Filed Dec 5, 2017 17:34 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 13,495 | $1.78 | $23,987.36 |
DisclosureSEC source: 0001012975-17-000916 · edgar.xml · nonDerivative · entry 3 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,168 F3 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.68 to $1.88 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 04, 2017 Filed Dec 5, 2017 17:34 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 7,300 | $1.81 | $13,195.48 |
DisclosureSEC source: 0001012975-17-000916 · edgar.xml · nonDerivative · entry 2 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,673 F2 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.78 to $1.84 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 17:34 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 5,215 | $1.80 | $9,404.73 |
DisclosureSEC source: 0001012975-17-000916 · edgar.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,373 F1 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.78 to $1.82 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 30, 2017 Filed Nov 30, 2017 17:38 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 12,978 | $1.84 | $23,815.93 |
DisclosureSEC source: 0001012975-17-000882 · edgar.xml · nonDerivative · entry 3 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,158 F3 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.80 to $1.90 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 29, 2017 Filed Nov 30, 2017 17:38 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 7,942 | $1.94 | $15,377.30 |
DisclosureSEC source: 0001012975-17-000882 · edgar.xml · nonDerivative · entry 2 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,180 F2 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.90 to $1.98 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 28, 2017 Filed Nov 30, 2017 17:38 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 12,395 | $1.97 | $24,445.42 |
DisclosureSEC source: 0001012975-17-000882 · edgar.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,238 F1 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.90 to $2.02 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 27, 2017 Filed Nov 27, 2017 17:31 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 10,042 | $2.00 | $20,059.90 |
DisclosureSEC source: 0001012975-17-000874 · edgar.xml · nonDerivative · entry 3 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,843 F3 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.95 to $2.03 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 24, 2017 Filed Nov 27, 2017 17:31 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 6,505 | $2.02 | $13,161.57 |
DisclosureSEC source: 0001012975-17-000874 · edgar.xml · nonDerivative · entry 2 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,801 F2 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $2.00 to $2.07 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 22, 2017 Filed Nov 27, 2017 17:31 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 5,261 | $2.10 | $11,060.73 |
DisclosureSEC source: 0001012975-17-000874 · edgar.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,296 F1 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $2.07 to $2.13 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 18:10 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 7,236 | $2.06 | $14,905.44 |
DisclosureSEC source: 0001012975-17-000867 · edgar.xml · nonDerivative · entry 3 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,035 F3 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $2.03 to $2.08 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 18:10 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 4,800 | $2.07 | $9,957.60 |
DisclosureSEC source: 0001012975-17-000867 · edgar.xml · nonDerivative · entry 2 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,799 F2 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $2.06 to $2.10 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 18:10 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 6,295 | $2.12 | $13,351.70 |
DisclosureSEC source: 0001012975-17-000867 · edgar.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,999 F1 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $2.11 to $2.15 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 20:20 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 20,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001012975-17-000769 · edgar.xml · derivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock, par value $0.0001 · 20,000 shares Expires 2027-10-13 Read SEC document |
| September 13, 2017 Filed Sep 14, 2017 17:07 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 5,000 | $17.50 | $87,500.00 |
DisclosureSEC source: 0000899243-17-022083 · doc4.xml · nonDerivative · entry 2 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,730 Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 17:07 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 10,000 | $17.50 | $175,000.00 |
DisclosureSEC source: 0000899243-17-022083 · doc4.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,730 Read SEC document |
| August 25, 2017 Filed Aug 28, 2017 16:56 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 50,000 | $2.25 | $112,390.00 |
DisclosureSEC source: 0001012975-17-000664 · edgar.xml · nonDerivative · entry 2 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,704 F2 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $2.20 to $2.25 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 24, 2017 Filed Aug 28, 2017 16:56 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 17,326 | $2.24 | $38,891.67 |
DisclosureSEC source: 0001012975-17-000664 · edgar.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,704 F1 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $2.13 to $2.28 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 23, 2017 Filed Aug 23, 2017 17:05 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 43,352 | $2.22 | $96,349.82 |
DisclosureSEC source: 0001012975-17-000654 · edgar.xml · nonDerivative · entry 3 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,378 F3 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $2.16 to $2.28 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 17:05 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 5,958 | $2.10 | $12,518.95 |
DisclosureSEC source: 0001012975-17-000654 · edgar.xml · nonDerivative · entry 2 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,026 F2 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $2.04 to $2.15 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 21, 2017 Filed Aug 23, 2017 17:05 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 690 | $2.02 | $1,394.70 |
DisclosureSEC source: 0001012975-17-000654 · edgar.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,068 F1 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $2.02 to $2.03 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 12, 2017 Filed May 16, 2017 17:43 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 5,000 | $16.55 | $82,750.00 |
DisclosureSEC source: 0000899243-17-013377 · doc4.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,730 Read SEC document |
| May 10, 2017 Filed May 12, 2017 16:05 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 10,000 | $15.75 | $157,500.00 |
DisclosureSEC source: 0000899243-17-012976 · doc4.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,730 Read SEC document |
| May 09, 2017 Filed May 10, 2017 16:17 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 10,000 | $14.75 | $147,500.00 |
DisclosureSEC source: 0000899243-17-012648 · doc4.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,730 Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 16:05 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 8,730 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005784 · doc4.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,730 Read SEC document |
| January 13, 2017 Filed Jan 17, 2017 16:16 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001144204-17-002438 · v457015_4.xml · derivative · entry 3 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2017 Filed Jan 17, 2017 16:16 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, $0.0001 par value per share | 20,000 | $2.20 | $44,000.00 |
DisclosureSEC source: 0001144204-17-002438 · v457015_4.xml · nonDerivative · entry 1 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,043,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 16:30 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001144204-16-126786 · v450001_4.xml · derivative · entry 15 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 16:30 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001144204-16-126786 · v450001_4.xml · derivative · entry 14 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2024-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 16:30 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001144204-16-126786 · v450001_4.xml · derivative · entry 13 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 16:30 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001144204-16-126786 · v450001_4.xml · derivative · entry 12 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 16:30 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001144204-16-126786 · v450001_4.xml · derivative · entry 11 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2020-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 16:30 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001144204-16-126786 · v450001_4.xml · derivative · entry 10 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2019-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 16:30 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001144204-16-126786 · v450001_4.xml · derivative · entry 9 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2018-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 16:30 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, $0.0001 par value per share | 20,000 | $1.69 | $33,800.00 |
DisclosureSEC source: 0001144204-16-126786 · v450001_4.xml · nonDerivative · entry 7 SCHAFFER DERACE L · CIK 0001031735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,023,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.